{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:51:28Z","timestamp":1790362288930,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08-AI139371"],"award-info":[{"award-number":["K08-AI139371"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AI145435-A1"],"award-info":[{"award-number":["R01-AI145435-A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ijantimicag.2023.107048","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T02:22:54Z","timestamp":1701742974000},"page":"107048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0971-3635","authenticated-orcid":false,"given":"Elizabeth W.","family":"Tucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo A.","family":"Ruiz-Bedoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Erice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-5916","authenticated-orcid":false,"given":"John","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-9069","authenticated-orcid":false,"given":"Patricia","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1940-1299","authenticated-orcid":false,"given":"Ravindra","family":"Jahdav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-000X","authenticated-orcid":false,"given":"Melissa","family":"Bahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Flavahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-7759","authenticated-orcid":false,"given":"Xueyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-7052","authenticated-orcid":false,"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Freundlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7070","authenticated-orcid":false,"given":"Sanjay K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.107048_bib0001","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0002","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41590-018-0119-x","article-title":"Tuberculous meningitis: a roadmap for advancing basic and translational research","volume":"19","author":"Jain","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0003","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1473-3099(14)70852-7","article-title":"Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis","volume":"14","author":"Chiang","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0004","series-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0005","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/AAC.47.1.416-417.2003","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs","volume":"47","author":"Alcala","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0006","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0007","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","article-title":"Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis","volume":"178","author":"Dietze","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1179\/joc.2010.22.1.17","article-title":"Linezolid penetration into cerebrospinal fluid and brain tissue","volume":"22","author":"Tsona","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0009","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/AAC.00515-06","article-title":"Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains","volume":"51","author":"Beer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0011","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0012","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1128\/AAC.02784-14","article-title":"Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis","volume":"58","author":"Sun","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0013","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/INF.0000000000001114","article-title":"Linezolid is associated with improved early outcomes of childhood tuberculous meningitis","volume":"35","author":"Li","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06705-4","article-title":"Decreased mortality seen in rifampicin\/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China","volume":"21","author":"Fang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0015","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1186\/s13063-022-06772-1","article-title":"Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial","volume":"23","author":"Maitre","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0016","doi-asserted-by":"crossref","first-page":"136","DOI":"10.12688\/wellcomeopenres.16783.1","article-title":"Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]","volume":"6","author":"Davis","year":"2021","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0017","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/cid\/ciac932","article-title":"A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus\u2013associated tuberculous meningitis: the LASER-TBM trial","volume":"76","author":"Davis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0018","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0019","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1473-3099(18)30480-8","article-title":"Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial","volume":"19","author":"Lee","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0020","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/cid\/ciab992","article-title":"Cycloserine and linezolid for tuberculosis meningitis: pharmacokinetic evidence of potential usefulness","volume":"75","author":"Kempker","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-35730-3","article-title":"Dynamic 18F-pretomanid PET imaging in animal models of TB meningitis and human studies","volume":"13","author":"Mota","year":"2022","journal-title":"Nat Commun"},{"issue":"470","key":"10.1016\/j.ijantimicag.2023.107048_bib0022","doi-asserted-by":"crossref","first-page":"eaau0965","DOI":"10.1126\/scitranslmed.aau0965","article-title":"Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. Sci","volume":"10","author":"Tucker","year":"2018","journal-title":"Transl Med"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0023","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41591-020-0770-2","article-title":"Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions","volume":"26","author":"Ordonez","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.107048_bib0024","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155851","article-title":"High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis","volume":"132","author":"Ruiz-Bedoya","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0025","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1242\/dmm.027326","article-title":"Microglia activation in a pediatric rabbit model of tuberculous meningitis","volume":"9","author":"Tucker","year":"2016","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0026","doi-asserted-by":"crossref","first-page":"R190","DOI":"10.1186\/ar2889","article-title":"Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment","volume":"11","author":"Rauchhaus","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0027","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0006-3223(02)01334-3","article-title":"HPA axis dysregulation in mice overexpressing corticotropin releasing hormone","volume":"51","author":"Groenink","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0029","author":"U.S. Food and Drug"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187187","article-title":"Linezolid and atorvastatin impact on pneumonia caused by Staphyloccocus aureus in rabbits with or without mechanical ventilation","volume":"12","author":"Pauchard","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0031","first-page":"407","article-title":"Bone tissue and plasma concentrations of linezolid and vancomycin in rabbits with prosthesis-related infection due to MRSA","volume":"64","author":"Swoboda","year":"2009","journal-title":"Pharmazie"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0032","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/cid\/ciw483","article-title":"Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: goldilocks","volume":"63","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0033","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/pharmaceutics9030034","article-title":"Comparative pharmacokinetic study for linezolid and two novel antibacterial oxazolidinone derivatives in rabbits: can differences in the pharmacokinetic properties explain the discrepancies between their in vivo and in vitro antibacterial activities?","volume":"9","author":"Hedaya","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0034","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1021\/acsinfecdis.9b00473","article-title":"Radiosynthesis and biodistribution of 18F-linezolid in Mycobacterium tuberculosis-infected mice using positron emission tomography","volume":"6","author":"Mota","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0035","doi-asserted-by":"crossref","first-page":"e6297","DOI":"10.1371\/journal.pone.0006297","article-title":"Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals","volume":"4","author":"Davis","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30053-7","article-title":"Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study","author":"van Laarhoven","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.ijantimicag.2023.107048_bib0037","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2024852118","article-title":"Elevated cerebrospinal fluid cytokine levels in tuberculous meningitis predict survival in response to dexamethasone","volume":"118","author":"Whitworth","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2023.102351","article-title":"Escalate: linezolid as an add on treatment in the intensive phase of tubercular meningitis. A randomized controlled pilot trial","volume":"142","author":"Sahib","year":"2023","journal-title":"Tuberculosis (Edinb)."},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0039","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/AAC.00775-08","article-title":"Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection","volume":"53","author":"Baldoni","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"622","key":"10.1016\/j.ijantimicag.2023.107048_bib0040","doi-asserted-by":"crossref","first-page":"eabl6851","DOI":"10.1126\/scitranslmed.abl6851","article-title":"Dynamic PET-facilitated modeling and high-dose rifampin regimens for Staphylococcus aureus orthopedic implant-associated infections","volume":"13","author":"Gordon","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0041","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2106\/JBJS.16.01002","article-title":"Oral-only linezolid-rifampin is highly effective compared with other antibiotics for periprosthetic joint infection: study of a mouse model","volume":"99","author":"Thompson","year":"2017","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0042","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40780-018-0123-1","article-title":"Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies","volume":"4","author":"Hashimoto","year":"2018","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214037","article-title":"Effects of a rifampicin pre-treatment on linezolid pharmacokinetics","volume":"14","author":"Okazaki","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.107048_bib0044","doi-asserted-by":"crossref","first-page":"e00822","DOI":"10.1128\/AAC.00822-18","article-title":"Use of translational pharmacokinetic\/pharmacodynamic infection models to understand the impact of neutropenia on the efficacy of tedizolid phosphate","volume":"63","author":"Xiao","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.107048_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00021-19","article-title":"Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0046","article-title":"Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis","author":"Abdelgawad","year":"2023","journal-title":"J Infect Dis."},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0047","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1517\/17425255.2013.786042","article-title":"Microdosing and drug development: past, present and future","volume":"9","author":"Lappin","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2023.107048_bib0048","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41573-020-0080-x","article-title":"Phase 0\/microdosing approaches: time for mainstream application in drug development?","volume":"19","author":"Burt","year":"2020","journal-title":"Nat Rev Drug Discov"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923003370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923003370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:49:35Z","timestamp":1760377775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923003370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0924857923003370"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107048","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107048"}}